tspan8 apc Search Results


tspan8 apc  (R&D Systems)
93
R&D Systems tspan8 apc
( A ) Schematic view of the experimental design. Stage 1 (PT, primary tumor) involved processing of tumors under physioxia and ambient air, flow cytometry characterization of cells, cell propagation, and reimplantation of cells into female FVB/N mice. Stage 2 (PL, primary line) involved flow cytometry characterization of cultured cells of stage 1. Stage 3 (TT, Transplanted Tumor) involved recharacterization of tumors obtained from cell implantation of stage 1. Stage 4 (TL, transplanted line) involved flow cytometry characterization of cells grown from stage 3 tumor. PT, Primary Tumor; PL, Primary Line; TT, Transplanted Tumor; TL, Transplanted Line. ( B ) Representative flow cytometry profile of tumor cells stained for antibodies against LGR5 and <t>TSPAN8.</t> Antibodies against lineage markers CD31-PE (phycoerythrin)/Cy7, CD45-PE/Cy7, and CD140a-PE/Cy7 were used to label endothelial cells, hematopoietic cells, and fibroblasts, respectively, and only lineage-negative cells were included in the analysis. ( C ) Quantitation of LGR5 + cells. Differences in LGR5 + cells between ambient air and physioxia are significant [ n = 3 to 6, one-way analysis of variance (ANOVA)]. ( D ) CD61/TSPAN8 staining patterns of tumor cells ( n = 3 to 6, one-way ANOVA). ( E ) Quantitation of TSPAN8 + cells. ( F ) Quantitation of CD61 + cells. ( G ) Tumor cells collected and processed at physioxia express higher levels of stemness-associated genes compared to ambient air ( n = 3, one-way ANOVA, P = 0.0004). * P < 0.05, ** P < 0.01, and *** P < 0.001 by ANOVA. ns, not significant.
Tspan8 Apc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tspan8 apc/product/R&D Systems
Average 93 stars, based on 1 article reviews
tspan8 apc - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
reafinitytm  (Miltenyi Biotec)
94
Miltenyi Biotec reafinitytm
( A ) Schematic view of the experimental design. Stage 1 (PT, primary tumor) involved processing of tumors under physioxia and ambient air, flow cytometry characterization of cells, cell propagation, and reimplantation of cells into female FVB/N mice. Stage 2 (PL, primary line) involved flow cytometry characterization of cultured cells of stage 1. Stage 3 (TT, Transplanted Tumor) involved recharacterization of tumors obtained from cell implantation of stage 1. Stage 4 (TL, transplanted line) involved flow cytometry characterization of cells grown from stage 3 tumor. PT, Primary Tumor; PL, Primary Line; TT, Transplanted Tumor; TL, Transplanted Line. ( B ) Representative flow cytometry profile of tumor cells stained for antibodies against LGR5 and <t>TSPAN8.</t> Antibodies against lineage markers CD31-PE (phycoerythrin)/Cy7, CD45-PE/Cy7, and CD140a-PE/Cy7 were used to label endothelial cells, hematopoietic cells, and fibroblasts, respectively, and only lineage-negative cells were included in the analysis. ( C ) Quantitation of LGR5 + cells. Differences in LGR5 + cells between ambient air and physioxia are significant [ n = 3 to 6, one-way analysis of variance (ANOVA)]. ( D ) CD61/TSPAN8 staining patterns of tumor cells ( n = 3 to 6, one-way ANOVA). ( E ) Quantitation of TSPAN8 + cells. ( F ) Quantitation of CD61 + cells. ( G ) Tumor cells collected and processed at physioxia express higher levels of stemness-associated genes compared to ambient air ( n = 3, one-way ANOVA, P = 0.0004). * P < 0.05, ** P < 0.01, and *** P < 0.001 by ANOVA. ns, not significant.
Reafinitytm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/reafinitytm/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
reafinitytm - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


( A ) Schematic view of the experimental design. Stage 1 (PT, primary tumor) involved processing of tumors under physioxia and ambient air, flow cytometry characterization of cells, cell propagation, and reimplantation of cells into female FVB/N mice. Stage 2 (PL, primary line) involved flow cytometry characterization of cultured cells of stage 1. Stage 3 (TT, Transplanted Tumor) involved recharacterization of tumors obtained from cell implantation of stage 1. Stage 4 (TL, transplanted line) involved flow cytometry characterization of cells grown from stage 3 tumor. PT, Primary Tumor; PL, Primary Line; TT, Transplanted Tumor; TL, Transplanted Line. ( B ) Representative flow cytometry profile of tumor cells stained for antibodies against LGR5 and TSPAN8. Antibodies against lineage markers CD31-PE (phycoerythrin)/Cy7, CD45-PE/Cy7, and CD140a-PE/Cy7 were used to label endothelial cells, hematopoietic cells, and fibroblasts, respectively, and only lineage-negative cells were included in the analysis. ( C ) Quantitation of LGR5 + cells. Differences in LGR5 + cells between ambient air and physioxia are significant [ n = 3 to 6, one-way analysis of variance (ANOVA)]. ( D ) CD61/TSPAN8 staining patterns of tumor cells ( n = 3 to 6, one-way ANOVA). ( E ) Quantitation of TSPAN8 + cells. ( F ) Quantitation of CD61 + cells. ( G ) Tumor cells collected and processed at physioxia express higher levels of stemness-associated genes compared to ambient air ( n = 3, one-way ANOVA, P = 0.0004). * P < 0.05, ** P < 0.01, and *** P < 0.001 by ANOVA. ns, not significant.

Journal: Science Advances

Article Title: Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity

doi: 10.1126/sciadv.abh3375

Figure Lengend Snippet: ( A ) Schematic view of the experimental design. Stage 1 (PT, primary tumor) involved processing of tumors under physioxia and ambient air, flow cytometry characterization of cells, cell propagation, and reimplantation of cells into female FVB/N mice. Stage 2 (PL, primary line) involved flow cytometry characterization of cultured cells of stage 1. Stage 3 (TT, Transplanted Tumor) involved recharacterization of tumors obtained from cell implantation of stage 1. Stage 4 (TL, transplanted line) involved flow cytometry characterization of cells grown from stage 3 tumor. PT, Primary Tumor; PL, Primary Line; TT, Transplanted Tumor; TL, Transplanted Line. ( B ) Representative flow cytometry profile of tumor cells stained for antibodies against LGR5 and TSPAN8. Antibodies against lineage markers CD31-PE (phycoerythrin)/Cy7, CD45-PE/Cy7, and CD140a-PE/Cy7 were used to label endothelial cells, hematopoietic cells, and fibroblasts, respectively, and only lineage-negative cells were included in the analysis. ( C ) Quantitation of LGR5 + cells. Differences in LGR5 + cells between ambient air and physioxia are significant [ n = 3 to 6, one-way analysis of variance (ANOVA)]. ( D ) CD61/TSPAN8 staining patterns of tumor cells ( n = 3 to 6, one-way ANOVA). ( E ) Quantitation of TSPAN8 + cells. ( F ) Quantitation of CD61 + cells. ( G ) Tumor cells collected and processed at physioxia express higher levels of stemness-associated genes compared to ambient air ( n = 3, one-way ANOVA, P = 0.0004). * P < 0.05, ** P < 0.01, and *** P < 0.001 by ANOVA. ns, not significant.

Article Snippet: The antibodies used against mouse cells were CD31-PE/Cyanine7 (A14715) from Molecular Probes; CD45-PE/Cyanine7 (25-0451-82), EpCAM-APC (allophycocyanin) (17-5791-82), and CD29-FITC (fluorescein isothiocyanate) (11-0291-82) from Invitrogen; CD140a-PE/Cyanine7 (323508) from BioLegend; LGR5-PE (phycoerythrin) (FAB8240P), TSPAN8-APC (FAB6524A), and CD49f-PE (FAB13501P) from R&D Systems; and CD61-FITC (561911), CD274-PE (558091), CD24-APC (562349), and CXCR4-FITC (551967) from BD Pharmingen; isotype control antibodies used included PE/Cyanine7 (400522) and APC (400612) from BioLegend and PE (554689) and FITC (553971) from BD Pharmingen.

Techniques: Flow Cytometry, Cell Culture, Staining, Quantitation Assay

Note that tumor cells for both conditions were derived from the same tumor. ( A ) Phase-contrast images of PyMT tumor–derived cells with and without drug treatment ( n = 3, one-way ANOVA). ( B ) Quantitative measurement of cell survival data from (A). DMSO, dimethyl sulfoxide. ( C ) Cell proliferation rate at variable concentrations of drugs was measured using bromodeoxyuridine incorporation enzyme-linked immunosorbent assay ( n = 6, one-way ANOVA). Cancer cells used in this experimental series and in (A) were derived from a different PyMT + and Her2/Neu + mice. ( D ) Mice with PyMT tumor xenograft developed from tumor cells collected and processed under ambient air and physioxia were administered daily with lapatinib (Lap) (100 mg/kg of body weight) or vehicle control (VC) via oral gavage for 25 days ( n = 10, Student’s t test). Tumor growth was monitored every 5 days for 25 days. Treatment was initiated only after tumors reached similar size in both groups. ( E ) LGR5/TSPAN8 staining pattern of tumor cells from PyMT tumor xenografts from (D) ( n = 3, one-way ANOVA). APC, allophycocyanin. ( F ) Quantitation of LGR5 + cells. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 by ANOVA and Student’s t test.

Journal: Science Advances

Article Title: Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity

doi: 10.1126/sciadv.abh3375

Figure Lengend Snippet: Note that tumor cells for both conditions were derived from the same tumor. ( A ) Phase-contrast images of PyMT tumor–derived cells with and without drug treatment ( n = 3, one-way ANOVA). ( B ) Quantitative measurement of cell survival data from (A). DMSO, dimethyl sulfoxide. ( C ) Cell proliferation rate at variable concentrations of drugs was measured using bromodeoxyuridine incorporation enzyme-linked immunosorbent assay ( n = 6, one-way ANOVA). Cancer cells used in this experimental series and in (A) were derived from a different PyMT + and Her2/Neu + mice. ( D ) Mice with PyMT tumor xenograft developed from tumor cells collected and processed under ambient air and physioxia were administered daily with lapatinib (Lap) (100 mg/kg of body weight) or vehicle control (VC) via oral gavage for 25 days ( n = 10, Student’s t test). Tumor growth was monitored every 5 days for 25 days. Treatment was initiated only after tumors reached similar size in both groups. ( E ) LGR5/TSPAN8 staining pattern of tumor cells from PyMT tumor xenografts from (D) ( n = 3, one-way ANOVA). APC, allophycocyanin. ( F ) Quantitation of LGR5 + cells. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 by ANOVA and Student’s t test.

Article Snippet: The antibodies used against mouse cells were CD31-PE/Cyanine7 (A14715) from Molecular Probes; CD45-PE/Cyanine7 (25-0451-82), EpCAM-APC (allophycocyanin) (17-5791-82), and CD29-FITC (fluorescein isothiocyanate) (11-0291-82) from Invitrogen; CD140a-PE/Cyanine7 (323508) from BioLegend; LGR5-PE (phycoerythrin) (FAB8240P), TSPAN8-APC (FAB6524A), and CD49f-PE (FAB13501P) from R&D Systems; and CD61-FITC (561911), CD274-PE (558091), CD24-APC (562349), and CXCR4-FITC (551967) from BD Pharmingen; isotype control antibodies used included PE/Cyanine7 (400522) and APC (400612) from BioLegend and PE (554689) and FITC (553971) from BD Pharmingen.

Techniques: Derivative Assay, Enzyme-linked Immunosorbent Assay, Control, Staining, Quantitation Assay